Home › Research › Lewy body dementia
Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration
Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, Bourakova V, Cobigo Y et al.. Nature medicine, 2020-03-02
Topic: Brain proteins, microglia and lab models
Plain-language summary
With the potential development of new disease-modifying Alzheimer's disease (AD) therapies, simple, widely available screening tests are needed to identify which individuals, who are experiencing symptoms of cognitive or behavioral decline, should be further evaluated for initiation of treatment. A blood-based test for AD would be a less invasive and less expensive screening tool than the currently approved cerebrospinal fluid or amyloid β positron emission tomography (PET) diagnostic tests. We examined whether plasma tau phosphorylated at residue 181 (pTau181) could differentiate between clinically diagnosed or autopsy-confirmed AD and frontotemporal lobar degeneration. Plasma pTau181 concentrations were increased by 3.5-fold in AD compared to controls and differentiated AD from both clinically diagnosed (receiver operating characteristic area under the curve of 0.894) and autopsy-confirmed frontotemporal lobar degeneration (area under the curve of 0.878). Plasma pTau181 identified individuals who were amyloid β-PET-positive regardless of clinical diagnosis and correlated with cortical tau protein deposition measured by 18 F-flortaucipir PET. Plasma pTau181 may be useful to screen for tau pathology associated with AD.
What this study adds
Evidence grade: Low
In this 2020 study, levels of a blood protein, plasma pTau181, were 3.5 times higher in people with Alzheimer's disease than in controls. The test separated Alzheimer's from frontotemporal lobar degeneration with an area under the curve of 0.894 against clinically diagnosed cases and 0.878 against autopsy-confirmed cases, and it also identified people who were amyloid-PET-positive and correlated with tau-PET.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Thijssen, E. H., La Joie, R., Wolf, A., Strom, A., Wang, P., Iaccarino, L., et al. (2020). Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. Nature medicine. https://doi.org/10.1038/s41591-020-0762-2
Vancouver
Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. Nature medicine. 2020. doi:10.1038/s41591-020-0762-2. PMID: 32123386.
BibTeX
@article{thijssen2020-32123386,
author = {Thijssen, E. H. and La Joie, R. and Wolf, A. and Strom, A. and Wang, P. and Iaccarino, L. and Bourakova, V. and Cobigo, Y. and others},
title = {{Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration}},
journal = {Nature medicine},
year = {2020},
doi = {10.1038/s41591-020-0762-2},
pmid = {32123386},
url = {https://doi.org/10.1038/s41591-020-0762-2}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Plasma pTau181 concentrations were increased by 3.5-fold in AD compared to controls and differentiated AD from both clinically diagnosed (receiver operating characteristic area under the curve of 0.894) and autopsy-confirmed frontotemporal lobar degeneration (area under the curve of 0.878).
- Plasma pTau181 may be useful to screen for tau pathology associated with AD.
Why it matters
In this 2020 study, levels of a blood protein, plasma pTau181, were 3.5 times higher in people with Alzheimer's disease than in controls. The test separated Alzheimer's from frontotemporal lobar degeneration with an area under the curve of 0.894 against clinically diagnosed cases and 0.878 against autopsy-confirmed cases, and it also identified people who were amyloid-PET-positive and correlated with tau-PET. The authors propose it as a cheaper, less invasive screen to decide which people with cognitive or behavioural symptoms should go on to fuller testing, not as a stand-alone diagnosis. The record does not report sample sizes, cut-offs or limitations.
Study details
- Evidence strengthLow
How this study scored 64/100
Published in a top-tier journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (Nature medicine) |
| Journal's citation record | 4 / 4 | Nature Medicine: journal h-index 763 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2020 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 759 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 94.9 citations a year over 8 year(s) since 2020 |
| Impact for its field and year | 6 / 6 | Cited 78.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 78 other studies in this library |
| Still being cited | 4 / 4 | Cited 265 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Adam L. Boxer: h-index 98 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 12 institution(s) in 4 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 32123386) |
| Free to read | 2 / 2 | Free to read |
| Total | 64 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1038/s41591-020-0762-2
- PubMed: 32123386
- Original source →
- Free full text: Pure Amsterdam UMC →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 45.
Later studies that cite this one
78 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Lewy body dementia from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.